Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1114 | 984 | 1216 | 1210 | 1346 | 1605 |
Fund Return | 11.41% | -1.59% | 21.57% | 6.55% | 6.12% | 4.84% |
Place in category | 40 | 217 | 89 | 74 | 136 | 122 |
% in Category | 10 | 63 | 12 | 23 | 41 | 63 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
JPM Global Income A acc EUR | 17.91B | 6.41 | -0.68 | 2.08 | ||
LU0740858492 | 17.91B | 6.10 | -1.03 | 1.72 | ||
JPMorgan Global Income A Div EUR | 17.91B | 6.41 | -0.68 | 2.08 | ||
JPM Global Income Fund A Mth EUR | 17.91B | 6.40 | -0.69 | - | ||
JPMorgan Global Income D div EUR | 17.91B | 6.10 | -1.03 | 1.73 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Equity Income Fund D2 EUR | 78.2M | 8.59 | 4.64 | 6.63 | ||
European Equity Income Fund D5GRF E | 19.37M | 8.56 | 4.64 | 6.63 | ||
European Equity Income Fund D4G EUR | 45.85M | 8.61 | 4.65 | 6.63 | ||
European Equity Income Fund I4G EUR | 6.23M | 8.80 | 4.92 | 6.91 | ||
BlackRock European Equity IncomeE5G | 100.4M | 7.48 | 3.35 | 5.31 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novartis | CH0012005267 | 2.35 | 92.75 | +0.89% | |
Novo Nordisk B | DK0062498333 | 2.30 | 743.4 | -2.03% | |
SAP | DE0007164600 | 2.24 | 220.150 | -1.37% | |
Shell | GB00BP6MXD84 | 2.10 | 30.72 | -0.52% | |
Roche Holding Participation | CH0012032048 | 1.95 | 252.50 | +0.44% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Strong Buy |
Technical Indicators | Strong Buy | Neutral | Strong Buy |
Summary | Strong Buy | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review